133
Views
13
CrossRef citations to date
0
Altmetric
Research Article

TIMP-1 polymorphisms in a Chinese Han population with intracerebral hemorrhage

, , , , , , , & show all
Pages 61-67 | Received 11 Sep 2012, Accepted 07 Jul 2013, Published online: 15 Aug 2013

References

  • Bonita R, Mendis S, Truelsen T, The global stroke initiative. Lancet Neurol 2004;3:391–3.
  • Labovitz DL, Halim A, Boden-Albala B, The incidence of deep and lobar intracerebral hemorrhage in whites, blacks, and hispanics. Neurology 2005;65:518–22.
  • Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet 2009;373:1632–44.
  • Flaherty ML, Haverbusch M, Sekar P, Long-term mortality after intracerebral hemorrhage. Neurology 2006;66:1182–6.
  • Woo D, Sauerbeck LR, Kissela BM, Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke 2002;33:1190–5.
  • Bak S, Gaist D, Sindrup SH, Genetic liability in stroke: a long-term follow-up study of Danish twins. Stroke 2002;33: 769–74.
  • Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol 2006;16:30–9.
  • Rosenblum WI. Fibrinoid necrosis of small brain arteries and arterioles and miliary aneurysms as causes of hypertensive hemorrhage: a critical reappraisal. Acta Neuropathol 2008; 116:361–9.
  • Rosenblum WI. Cerebral hemorrhage produced by ruptured dissecting aneurysm in miliary aneurysm. Ann Neurol 2003;54:376–8.
  • Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and timps. Cardiovasc Res 2006;69: 562–73.
  • Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251–62.
  • Fatar M, Stroick M, Griebe M, Hennerici M. Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis 2005; 20:141–51.
  • Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998;18: 1163–72.
  • Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009;158:983–94.
  • Montaner J, Molina CA, Monasterio J, Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598–603.
  • Montaner J, Fernandez-Cadenas I, Molina CA, Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (c-1562t) in the promoter region of the matrix metalloproteinase-9 gene. Stroke 2003;34:2851–5.
  • Castellanos M, Leira R, Serena J, Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003;34: 40–6.
  • Barr TL, Latour LL, Lee KY, Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 2010;41:e123–8.
  • Abilleira S, Montaner J, Molina CA, Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg 2003;99:65–70.
  • Li N, Liu YF, Ma L, Association of molecular markers with perihematomal edema and clinical outcome in intracerebral hemorrhage. Stroke 2013;44:658–63.
  • Wu CH, Huang FY, Wang KY, Expression of matrix metalloproteinase mmp-9 in the plasma and hematoma fluid of intracerebral hemorrhage patients. Zhonghua Yi Xue Za Zhi 2008;88:174–6.
  • Alvarez-Sabin J, Delgado P, Abilleira S, Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke 2004;35:1316–22.
  • Tejima E, Guo S, Murata Y, Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase timp-1. J Neurotrauma 2009;26:1935–41.
  • Timms PM, Wright A, Maxwell P, Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens 2002;15:269–72.
  • Onal IK, Altun B, Onal ED, Serum levels of mmp-9 and timp-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Med 2009;20:369–72.
  • Gaubatz JW, Ballantyne CM, Wasserman BA, Association of circulating matrix metalloproteinases with carotid artery characteristics: the atherosclerosis risk in communities carotid MRI study. Arterioscler Thromb Vasc Biol 2010;30: 1034–42.
  • Kruk M, Kalinczuk L, Pregowski J, Serum tissue inhibitor of metalloproteinases-1 and higher risk features of coronary plaque: a volumetric multivessel intravascular ultrasound study. Atherosclerosis 2007;194:e57–63.
  • Tsarouhas K, Soufla G, Apostolakis S, Transcriptional regulation of timps in ascending aorta aneurysms. Thromb Res 2010;126:399–405.
  • Aoki T, Kataoka H, Moriwaki T, Role of timp-1 and timp-2 in the progression of cerebral aneurysms. Stroke 2007;38:2337–45.
  • Ogata T, Shibamura H, Tromp G, Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. J Vasc Surg 2005;41: 1036–42.
  • Hinterseher I, Krex D, Kuhlisch E, Tissue inhibitor of metalloproteinase-1 (timp-1) polymorphisms in a Caucasian population with abdominal aortic aneurysm. World J Surg 2007;31:2248–54.
  • Reuter B, Bugert P, Stroick M, Timp-2 gene polymorphism is associated with intracerebral hemorrhage. Cerebrovasc Dis 2009;28:558–63.
  • Purcell S, Neale B, Todd-Brown K, Plink: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559–75.
  • Purcell S, Cherny SS, Sham PC. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003;19:149–50.
  • Yang QD, Niu Q, Zhou YH, Incidence of cerebral hemorrhage in the Changsha community. A prospective study from 1986 to 2000. Cerebrovasc Dis 2004;17:303–13.
  • Sundstrom J, Vasan RS. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 2006;17:45–53.
  • Hansson J, Lind L, Hulthe J, Sundstrom J. Relations of serum mmp-9 and timp-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study. Eur J Cardiovasc Prev Rehabil 2009;16:297–303.
  • Sundstrom J, Evans JC, Benjamin EJ, Relations of plasma total timp-1 levels to cardiovascular risk factors and echocardiographic measures: the framingham heart study. Eur Heart J 2004;25:1509–16.
  • Hansson J, Vasan RS, Arnlov J, Biomarkers of extracellular matrix metabolism (mmp-9 and timp-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study. PLoS ONE 2011;6:e16185.
  • Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002;53:550–7.
  • Yang X, Schadt EE, Wang S, Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res 2006;16:995–1004.
  • Chaturvedi M, Figiel I, Sreedhar B, Kaczmarek L. Neuroprotection from tissue inhibitor of metalloproteinase-1 and its nanoparticles. Neurochem Int 2012;61:1065–71.
  • Zhang L, Yang QD, Zeng Y, Positive association of apolipoprotein b gene c7673t polymorphism with cerebral hemorrhage with family history. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2008;25:145–9.
  • Hu ZY, Zhang L, Yang QD, Effect of apob polymorphism on plasma lipid levels and cerebral hemorrhage in Changsha Han Chinese. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008;33:494–99.
  • Bednarek N, Svedin P, Garnotel R, Increased mmp-9 and timp-1 in mouse neonatal brain and plasma and in human neonatal plasma after hypoxia-ischemia: a potential marker of neonatal encephalopathy. Pediatr Res 2012;71:63–70.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.